Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

February 9, 2018: By Jon Swedien

Second SightSecond Sight announced Feb. 5 that surgeons implanted 30 Argus II Retinal Prosthesis Systems worldwide in Q4-2017.

The total sets a quarterly record and is a more than three-fold increase over the seven Argus II systems implanted in Q4-2016.

For the full year, Second Sight reported 75 Argus II implantations, a 79 percent increase over 42 implantations in 2016.

The Argus II converts images captured by a miniature video camera mounted on a patient’s glasses into a series of small electrical pulses. It is designed to induce visual perception in individuals with severe to profound retinitis pigmentosa.

The Argus II had a Medicare reimbursement rate of $150 thousand in 2017, a sharp increase from $95 thousand in 2016.

The 2018 rate is $122,500.

Orion’s First Human Patient

The company also reported Feb. 5 that Nader Pouratian, MD, PhD, implanted the first human patient with the Orion Cortical Visual Prosthesis System.

The Orion works similarly to the Argus II, though it is implanted on the surface of the visual cortex.

Second Sight said a cortical prosthesis system, which bypasses the retina and optic nerve and directly stimulates the visual cortex, has the potential to restore useful vision to patients blinded due to many reasons, including glaucoma, diabetic retinopathy, or forms of cancer and trauma.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility